Drug Approval | October 07, 2023
Lupin receives tentative approval from USFDA for Tolvaptan Tablets
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
The World Homoeopathy Day commemorates the birth anniversary of Dr Samuel Hahnemann on 10th of April
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
Subscribe To Our Newsletter & Stay Updated
